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Objective: Our previous study demonstrated that high flow conditions stimulated cell proliferation in the aortic wall in a
rat model of abdominal aortic aneurysm (AAA), and we speculated that there is a possible relation between medial cell
density and aortic wall integrity. In the present study we delivered the basic fibroblast growth factor (bFGF) gene to the
aortic wall of a rat AAA model and evaluated the effects of growth factor–enhanced smooth muscle cell (SMC)
proliferation on aneurysm progression.
Methods: AAA was induced in rats by means of infusion of porcine pancreatic elastase. Immediately after elastase infusion
the abdominal aorta was filled with an expression plasmid vector containing the bFGF gene (bFGF group) or LacZ gene
(control group); then gene transfer to the aortic wall was carried out with an in vivo electroporation method. The animals
were killed 7 days after treatment, and the aneurysm was measured. The numbers of SMCs, macrophages, and endothelial
cells were counted with immunostaining, and cell replication was evaluated with bromodeoxyuridine (BrdU) staining.
Results: Aneurysm diameter in the bFGF group was significantly smaller than that in the control group (4.6 0.3 mm vs
6.5 1.4 mm; P < .01). The numbers of medial SMCs and BrdU-incorporated cells in the bFGF group were significantly
greater than those in the control group (SMC, 101 34 per high-power field [hpf] vs 80 31/hpf; P < .05, BrdU, 107
 63/hpf vs 50 33/hpf; P < .05), whereas no difference was detected in the numbers of macrophages and endothelial
cells between the 2 groups.
Conclusions: Delivery of bFGF to the aortic wall induced significant enhancement of medial SMC proliferation, without
an increase in inflammatory infiltration, then successfully limited aneurysm enlargement. These findings suggest that
increased medial cellularity inhibits aneurysm formation, which possibly offers a clue for developing a new strategy for
treatment of AAAs. (J Vasc Surg 2004;40:512-8.)
Clinical Relevance: Small abdominal aortic aneurysms with intima and media not completely damaged would be a good
indication for this therapeutic gene transfer. The walls of large abdominal aortic aneurysms usually exhibit few viable
intimal or medial cells, and it is thus not possible to induce cell proliferation. Among various components of the aortic
wall, we focused on local cellularity as one of the protective mechanisms against aneurysm expansion. Although it is
difficult to directly apply the present method using electroporation to abdominal aorta in human beings because of its risk
for complication from electrical damage, advances in gene delivery techniques might realize the strategy of this study in
the future.Abdominal aortic aneurysm (AAA) is recognized as a
life-threatening vascular disease, but the pathologic mech-
anisms of AAA formation are not well understood. Mor-
phologic analyses of clinical specimens of the aneurysm wall
demonstrate some characteristic findings associated with
AAAs, including chronic infiltration of inflammatory cells,
degradation of extracellular matrix, and apoptosis of
smooth muscle cells (SMCs).1,2 In particular, because ex-
tracellular matrix sustains the strength and elasticity of the
aortic wall, many studies have focused on the mechanisms
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(MMPs), released from inflammatory and other cells, have
been considered to have an important role in matrix deg-
radation and aneurysm formation.3,4 MMP inhibition by
drugs or gene disruption prevents development of AAAs in
experimental animal models,5,6 and clinical studies show
evidence indicating upregulated activity of MMPs in pa-
tients with AAAs.7,8 However, recent studies have revealed
that increased MMP-9 activity does not necessarily predict
AAA progression in all cases.9,10
We previously evaluated the effects of wall shear stress
and relative wall strain on aneurysm formation, and re-
ported that high wall shear stress and relative wall strain
suppressed enlargement of the aorta in a rat elastase-
induced AAA model.9-11 Further, histologic analysis re-
vealed marked proliferation of medial SMCs in the aortic
wall subjected to high wall shear stress and relative wall
strain, accompanied by upregulation of mitogenic gene
expression.9 Because SMCs in the vascular wall are an
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collagen, we hypothesized that enhanced cellularity of the
medial layer stabilized aortic integrity. Basic fibroblast
growth factor (bFGF) possesses potent mitogenic activity
for vascular SMCs in vivo.12,13 In the present study, there-
fore, we delivered the gene for bFGF to the aortic wall of a
rat AAA model by means of an in vivo electroporation
technique and evaluated whether cell proliferation in the
aortic wall is associated with AAA formation.
MATERIAL AND METHODS
Plasmid. Plasmid pCAcchbFGFcs23 was constructed
by inserting a modified human bFGF complementary DNA
with the secretory signal sequence into the pCAGGS expres-
sion vector. The cDNA of modified human bFGF fused with
the signal sequence of interleukin-2 was obtained from plas-
mid pTB1079 (donated by Dr. K. Igarashi, Biotechnology
Research Laboratories, Takeda Chemical Industries, Osaka,
Japan). The control plasmid for the animal experiment was
pCAZ3, which contains Escherichia coli LacZ in the same
expression plasmid. Plasmids were grown in E coli JM109, and
were prepared with Qiagen EndoFree Mega Kits.
In vitro study. To evaluate expression and secretion
of bFGF from pCAcchbFGFcs23-treated rat cells, the plas-
mid pCAcchbFGFcs23 (15 g) was transfected into 1.5 
106 cultured rat vascular SMCs (from thoracic aorta, pas-
sage 4) by a method that used polyethylenimine (Ex Gen
500; MBI Fermentas). After transfection, SMCs were cul-
tured in 3 mL of Dulbecco modified Eagle minimum
Fig 1. In vivo gene transfer to aortic wall. a, A pair of ele
b, After elastase infusion, plasmid solution was pooled
appeared along the electrode during electric pulsation.essential medium (Gibco BRL) containing 2% fetal bovine
serum in a 6-cm dish. The culture medium was changed at
24-hour intervals, and the medium was harvested at 3 days
after transfection. Culture medium of non-transfected
SMCs was used as control medium. Each culture medium
(50 L) was subjected to Western blot analysis with a
mouse monoclonal antibody against bovine bFGF (1:500;
Santa Cruz Biotechnology) according to a protocol de-
scribed previously.14 This analysis was repeated twice.
Rat AAA model. Male Sprague-Dawley rats (3-4
months; Saitama Rabbitry), fed a normal diet, were used in
all experiments. Surgical procedures were performed under
sterile conditions with a stereomicroscope, and all proto-
e plates was positioned on the isolated abdominal aorta.
0 minutes, followed by electroporation. Small bubbles
Fig 2. In vitro study for confirmation of plasmid transfer. Plasmid
containing modified human basic fibroblast gene factor (bFGF) gene
was transfected into cultured rat smooth muscle cells (SMCs). Culture
medium of pCAcchbFGFcs23-treated SMCs (lanes 5-7) showed 2
forms of bFGF (18 and 22 kD), whereas medium samples of non-
transfected SMCs (lanes 2-4) showed no band. Lane 1, molecular size
marker.ctrod
for 2
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Animals (National Institutes of Health Publ. No. 85-23,
revised 1996). After anesthesia with intraperitoneal injec-
tion of 50 mg/kg of sodium pentobarbital (Abbott), a
10-mm segment of the infrarenal aorta was exposed and
completely isolated from adjacent connective tissue, and
the maximum diameter of the exposed aorta was measured
with electronic microcalipers in systole. Elastase was in-
fused according to the method of Anidjar and Dobrin with
modifications as described.15,16 In brief, PE-10 tubing was
advanced into the infrarenal aorta from the right deep
femoral artery. The proximal and distal parts of the infrare-
nal aorta were clamped by means of temporary ligation, and
subsequently 15 units of type 1 porcine pancreatic elastase
(E-1250; Sigma) in 2 mL of normal saline solution was
infused over 2 hours through the PE-10 tube.
In vivo gene transfer to aortic wall. After elastase
infusion, residual elastase solution was washed out with
2 mL of saline solution, and pCAcchbFGFcs23 (120 g)
Fig 3. In vivo expression of transfected gene. a, Fro
electroporation of LacZ (100). X-gal staining show
analysis revealed that pCAcchbFGFcs23-treated sam
pCAZ3-treated samples (lanes 5-7). Lane 1, Molecular
quantified. Values are shown as mean  SD. *P 
pCAZ3-treated samples.diluted with 300 L of phosphate-buffered saline solution
was gently infused within physiologic pressure through the
PE-10 tube, and the isolated aorta was incubated for 20
minutes (bFGF group). A pair of stainless steel electrode
plates (10  2 mm) were then positioned on the left and
right sides of the infrarenal aortic wall (Fig 1, a and b), and
electric pulses were delivered with an electric pulse gener-
ator (ECM 830; BTX); 5 square wave pulses of 15 V were
followed by 5 pulses of opposite polarity at a rate of 1 pulse
per second, with pulse duration of 50 ms.17 One group of
rats was subjected to incubation with pCAZ3 in the same
manner as control (control group). To confirm in vivo gene
transfer to the aortic wall, pCAZ3-treated rats were killed 2
days after gene transfer, and frozen sections of the aorta
were analyzed with X-gal staining. Further, pCAcchbFG-
Fcs23-treated or pCAZ3-treated rats (n 3 for each treat-
ment) were killed on day 2 to assess in vivo expression of
bFGF. Fresh aortic samples were rinsed with cold phos-
phate-buffered saline solution and lysed in lysis buffer (1%
section of aortic wall 2 days after elastase infusion/
uccessful transfection (blue, arrow). b, Western blot
lanes 2-4) showed higher expression of bFGF than
arker. c, Densities of the bands on Western blot were
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62.5 mmol/L of Tris [pH 7.6], 1 mmol/L of phenylmeth-
ylsulfonyl fluoride, and 10 mg/mL of leupeptin), and the
protein concentration was measured with a bicinchonic
acid assay (Pierce Biotechnology). Equal amounts (20 g
total protein) of each lysate were subjected to Western blot
analysis with anti-bFGF antibody. The density of the bands
on Western blots was quantified as described.18 Total val-
ues of bFGF expression were determined by summing
density values from all bFGF bands, and were used for
statistical analysis.
Measurement of aneurysm and histologic findings.
Seven days after operation the maximum diameter of the
aneurysm was measured with electronic microcalipers, and
then the rats were killed. For histologic analysis animals of
both groups were perfused with 4% paraformaldehyde solu-
tion in 0.1 mol/L of phosphate buffer (pH 7.4) through the
common iliac artery at 120 mm Hg, and the infrarenal aorta
was excised. After 1-hour immersion in the same fixative, the
aortic sample was divided into 2 segments (proximal and distal
segments) and embedded in paraffin. One set of sections (4
m) was stained with hematoxylin, and the luminal area (AL)
of the aortic section was measured as described.9 To standard-
ize the values of AL, the area inside the external elastic lamina
(AEEL) was measured, and the luminal area index was calcu-
lated as AL/ AEEL. Other sets of sections were immunostained
for smooth muscle actin, macrophages, and CD31. A mono-
Fig 4. Maximum diameter of infrarenal aorta (a), and lu
greater in bFGF group than in control group, whereas
shown as mean  SD. *P  .01, NS, no significant diffeclonal antibody against human -smooth muscle actin (1:
400; Sigma-Aldrich), rat macrophage (1:100; Chemicon), or
mouse CD31 (20 g/mL; Santa Cruz Biotechnology) was
applied after blocking with 1% goat serum. Subsequent incu-
bation with biotinylated anti-mouse immunoglobulin G anti-
body for 30 minutes and application of an avidin-biotin com-
plex method kit (Vector Laboratories) were performed.
Control slides were stained with a matching concentration of
non-immune mouse immunoglobulin G rather than primary
antibodies. Cell count was carried out on each slide at 200
magnification. To measure the SMC density in the aortic
medial layer, -smooth muscle actin-positive cells per hpf
were counted in 4 hpf per section (2 pairs of randomly selected
opposing hpf) and averaged.9 The density of macrophages in
the aortic media was evaluated in the same manner. For
evaluation of de-endothelialization of the aortic lumen,
CD31-positive cells on the luminal surface (endothelial cells)
were counted. The average of each value from 2 sections per
animal was used for statistical analysis.
Cell proliferation. At 1 hour before sacrifice, rats
received an intraperitoneal injection of 5-bromo-2=-
deoxyuridine (BrdU; 50 mg/kg) for analysis of cell prolif-
eration. Replicating cells in each section were stained with a
monoclonal antibody against BrdU (1:50; DAKO) as de-
scribed.9 BrdU-positive nuclei in the entire circumference
of the aortic media were counted as an index of aortic cell
l area index (b). Average maximum diameter at day 7 was
fference was detected in luminal area index. Values are
. Cont, control group; bFGF, bFGF group.mina
no di
rence
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per animal was used for statistical analysis.
Statistical analysis. To prevent bias in the evaluation,
a single student helper performed all histologic cell count-
ing in blinded fashion. Results were expressed as mean 
SD. Comparisons between groups were made with either
paired or unpaired 2-tailed t tests, with significance deter-
mined at P  .05.
RESULTS
In vitro study. Western blot analysis showed that
pCAcchbFGFcs23-treated rat SMCs secreted 2 forms of
bFGF (18 and 22 kD) into the culture medium at 3 days
after transfection, whereas no expression of bFGF was
detected in the culture medium of non-transfected SMCs
(Fig 2).
In vivo expression of transduced gene. To deter-
mine in vivo expression of the transduced gene, pCAZ3-
treated aortic samples were analyzed with X-gal staining,
Fig 5. Photomicrographs of aneurysm wall from contr
(200). c, Sections were immunostained with anti--sm
cells stain brown. Medial smooth muscle cell density was
4 high-power fields per section and averaging these valu
in the same manner. e, CD31-positive cells on the lumin
as mean  SD. *P  .01. NS, No significant difference.and abundant expression of LacZ was shown as blue stain-
ing (Fig 3, a). Western blot analysis detected bFGF expres-
sion in rat aortic wall incubated with pCAcchbFGFcs23
and also pCAZ3, and expression in pCAcchbFGFcs23-
treated samples was significantly higher than that in
pCAZ3-treated samples (Fig 3, b and c). Another form (21
kD) of bFGF was detected in the aortic wall in vivo.
Measurement of aneurysm diameter. Aneurysmal
changes in the infrarenal aorta were observed in all rats at 7
days after elastase treatment and gene transfer. Maximum
diameter of the aneurysms in the bFGF group was signifi-
cantly smaller than that in the control group (Fig 4, a).
Luminal area index showed no significant difference be-
tween the 2 groups (Fig 4, b).
Cell number. SMCs were stained with anti--smooth
muscle actin antibody, and the number of medial SMCs was
significantly increased in samples from the bFGF group com-
pared with the control group 7 days after operation (Fig 5,
a-c). In contrast, counting of macrophages in the aortic media
oup (a) and bFGF group (b) at 7 days after treatment
muscle actin antibody. -Smooth muscle actin-positive
ated by counting -smooth muscle actin-positive cells in
Density of macrophages in aortic media was quantified
face (endothelial cells) were counted. Values are shown
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trol groups (Fig 5, d). Furthermore, few scattered endothelial
cells were detected in any samples of aortic wall, and there was
no significant difference between the groups (Fig 5, e).
Medial cell proliferation. Immunostaining with anti-
BrdU antibody demonstrated proliferating cells in the aor-
tic wall, and medial cell proliferation in the bFGF group was
significantly greater than that in the control group (Fig 6,
a-c).
DISCUSSION
The purpose of this study was to evaluate whether
enhanced aortic cellularity reduces aneurysmal degenera-
tion and progressive increase in diameter in a rat elastase-
induced AAA model. Unlike previous experiments in which
aortic cellularity was modified in response to variable flow
conditions,9 in this case medial SMC proliferation was
stimulated by upregulation of bFGF gene expression. Al-
though used primarily to effect gene transfer in cultured
cells, recent work suggests that electroporation efficiently
transfers plasmid DNA to tissues and organs in vivo.17,19
Matsumoto et al17 reported that in vivo electroporation
enhanced gene expression after plasmid-based gene transfer
more than 10-fold in a rabbit carotid artery. We modified
these methods to transfect and upregulate bFGF gene
expression in rat elastase-treated aorta. Indeed, in the in
vivo evidence from the present study, bFGF expression in
the pCAcchbFGFcs23-treated aorta was greater than that
in the pCAZ3-treated aorta, which might be endogenous
bFGF expression in the aorta of this model.14,20 Linking
the bFGF gene to the secretory signal sequence of interleu-
kin-2 enabled successful extracellular transport, as con-
firmed with Western blotting in our cultured rat SMCs (Fig
2). It is presumed that augmenting bFGF expression stim-
ulated cell replication and increased medial SMC density in
transfected rats. It is important that no meaningful change
was detected in the number of aortic macrophages or
endothelial cells in bFGF-treated animals.
That bFGF treatment status influenced AAA diameter
in these experiments supports and extends our previous
observations regarding the role of medial SMC density in
maintaining aortic structural integrity.9 Although increased
medial cellularity is one of many potential anti-aneurysmal
consequences of increased aortic flow,9,11 this experimental
design facilitates analysis of SMC proliferation and reten-
tion independent of changes in wall shear stress or relative
wall strain. Medial SMCs synthesize and assemble collagen
and elastin precursors, maintain matrix organization, and
mediate the tensile characteristics of the aortic wall. It
seems self-evident, therefore, that reduced medial SMC
density compromises aortic integrity and facilitates aneu-
rysmal degeneration. Medial SMC apoptosis and cell loss is
a morphologic hallmark of AAAs in human beings, possibly
induced by inflammatory cytokines and reactive oxygen
species released from accumulated inflammatory cells.21,22
The findings of the current study strengthen the association
between medial SMC density and aortic structural integrityin experimental models, and suggest new treatment strate-
gies to limit the progression of clinical AAA disease.
Alternative explanations for the observed results include
the possibility that increased bFGF directly suppresses aneu-
rysm progression independent of its effect on medial SMC
density. Previous in vitro work suggests that bFGF inhibits
transendothelial monocyte migration and downregulates ex-
pression of proinflammatory endothelial adhesion mole-
cules.23 These effects may limit aortic wall inflammation after
bFGF gene transfer, potentially inhibiting aneurysm progres-
sion in this manner. No significant difference in medial mac-
rophage accumulation was noted between the bFGF and
control groups in this study, however, which suggests that the
anti-inflammatory consequences of increased bFGF expres-
sion are negligible in this context. These findings support our
conclusion that growth factor–mediated SMC proliferation is
the most likely explanation for limited aneurysm progression
in these experiments.
The exact mechanisms by which increased SMC density
limits AAA progression remains unknown. Investigations
Fig 6. Photomicrographs of aneurysm wall from control group
(a) and bFGF group (b) at 7 days after treatment (400). Sections
were immunostained with anti-bromodeoxyuridine (BrdU) anti-
body and counterstained with hematoxylin. BrdU-positive cells
stain brown. Cell replication in the media was evaluated by count-
ing BrdU-positive cells. Values are shown as mean SD. *P .05.
Cont, control group; bFGF, bFGF group.
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interactions between various cells types in the extracellular
matrix. Matrix homeostasis is a balance of synthesis and
degradation. Several matrix molecules contribute to aortic
architecture, and degradation is regulated by conflicting
systems of proteases and inhibitors generated by infiltrative
inflammatory cells as well as SMCs and endothelial
cells.24,25 Inasmuch as different cell types with ubiquitous
functions are present in or migrate to the aneurysm wall at
varyious times during the course of the disease, experimen-
tal data using whole specimens of aortic wall have proved to
be of limited value in clarifying the cause of the disease
process. Indeed, neither real-time reverse transcription
polymerase chain reaction nor gelatin zymography analyses
using whole aortic samples provided meaningful insight in
the present study (data not shown). To determine cell-
specific gene expression in the aneurysm wall it might be
necessary to use experimental methods that isolate groups
of cells within organs, such as laser-capture microdissec-
tion.26 We are adopting these methods to facilitate analysis
of cell-specific gene expression and further define the influ-
ence of increased medial SMC density on AAA progression.
In conclusion, we delivered the bFGF gene to enhance
medial cell density in the aortic wall of a rat elastase-induced
AAA model and assessed the relation between medial cellular-
ity and AAA formation. In vivo electroporation was used to
deliver the bFGF gene, and gene-transferred cells released
bFGF, because the bFGF gene was fused with the signal
sequence. The dominant component of the enhanced cellu-
larity was SMCs, and no increase in macrophages or endothe-
lial cells was observed. At 7 days after elastase treatment and
gene transfer of bFGF, aneurysm size was significantly smaller
than that of control. These findings suggest that enhancement
of medial cell density inhibited aneurysm formation after
elastase treatment, which possibly offers a clue for develop-
ment of a new strategy for AAA treatment.
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